LOGIN
Romosozumab has no impact on radiographic or clinical outcomes following hip fracture ORIF
February 2020
Romosozumab has no impact on radiographic or clinical outcomes following hip fracture ORIF
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
J Bone Joint Surg Am.2020Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Hip fractures are one of the leading causes of disability worldwide, and continue to grow in numbers given the aging global population. When hip fractures are repaired with open reduction, internal fixation, there is concern about the bone quality and healing potential in this population. Thus, numerous different therapies have been investigated recently in an effort to promote bone healing in thi...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.